3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3yl)-2,5-furandione | 133053-47-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3yl)-2,5-furandione
• 英文别名: 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione；3-(indol-3-yl)-4-(1-methyl-indol-3-yl)-furan-2,5-dione；3-(1-Methyl-indol-3-yl)-4-(indol-3-yl)-furan-2,5-dione；3-(1H-indol-3-yl)-4-(1-methylindol-3-yl)furan-2,5-dione
• CAS: 133053-47-1
• 化学式: C₂₁H₁₄N₂O₃
• 分子量: 342.354
• InChiKey: FXSDQXPAMGLPQX-UHFFFAOYSA-N

物化性质

• 熔点：
  246-248 °C
• 沸点：
  652.0±55.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3yl)-2,5-furandione 在 乙酸铵 作用下， 以70%的产率得到3-[(1-methyl)-3-indolyl]-4-(3-indolyl)-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Synthesis of a NovelN‐Nitroalkyl Bisindolylmaleimide

  摘要：

  DOI：

  10.1080/00397910701319205
• 作为产物：
  描述：

  1-methylindole-3-glyoxylyl chloride 在 sodium hydroxide 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3yl)-2,5-furandione
  参考文献：
  名称：

  Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides

  摘要：

  The design and synthesis of a series of novel inhibitors of protein kinase C (PKC) is described. These 2,3-bisarylznaleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. 2,3-Bisindolylmaleimides were the most active, and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (compound 28, IC50 0.11-mu-M). In a series of (phenylindolyl)maleimides, nitro compound 74 was most active (IC50 0.67-mu-M). Naphthalene 19 and benzothiophene 21 showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase (PKA).

  DOI：

  10.1021/jm00079a024

文献信息

• Pharmaceutically active compounds
  申请人：Astra Aktiebolag

  公开号：US06153641A1

  公开（公告）日：2000-11-28

  The present invention provides novel compounds of the formula (I): R.sub.20 --(CH.sub.2).sub.n --R (I) wherein: T.sub.20 is a bisindolylmaleimide moiety linked to the --(CH.sub.2).sub.n -group through an indolyl nitrogen, n is 0 or 1, R is a 5 or 6 membered aromatic carbocyclic or heterocyclic ring, the heterocyclic ring containing N or S, R is substituted by R.sub.1 and up to four of R.sub.2, R.sub.3, R.sub.4 and R.sub.5, wherein; R.sub.1 is aminomethyl, (N--(C.sub.1-4 -alkyl)amino)methyl, (N,N-di(C.sub.1-4 -alkyl)amino)methyl or pyridiniummethyl, and R.sub.2, R.sub.3, and R.sub.4 and R.sub.5 (if present), which may be the same or different, are each hydrogen, hydroxy, C.sub.1-4 -alkoxy, C.sub.1-4 -alkoxy) or halogen, or R.sub.2 when in a position contiguous to the bond connecting R to the --(CH.sub.2).sub.n -- group and n is 1 may, together with the 2-carbon atom on the indole to which the --(CH.sub.2) group is attached, form a ring, and pharmaceutically acceptable salts thereof; and the use of such compounds in medical therapy.

  本发明提供了一种新颖的公式(I)化合物：R.sub.20 --(CH.sub.2).sub.n --R (I) 其中：T.sub.20 是一个双吲哚基马来酰亚胺部分，通过吲哚基氮与--(CH.sub.2).sub.n -组连接，n为0或1，R是一个5或6成员的芳香碳环或杂环，杂环含有N或S，R被R.sub.1和最多四个R.sub.2，R.sub.3，R.sub.4和R.sub.5取代，其中；R.sub.1是氨基甲基，(N--(C.sub.1-4 -烷基)氨基)甲基，(N,N-二(C.sub.1-4 -烷基)氨基)甲基或吡啶甲基，R.sub.2，R.sub.3和R.sub.4和R.sub.5（如果存在），可能是相同的或不同的，每一个都是氢，羟基，C.sub.1-4 -烷氧基，C.sub.1-4 -烷氧基)或卤素，或者当R.sub.2处于连接R到--(CH.sub.2).sub.n --组的键的邻近位置且n为1时，R.sub.2可以与吲哚上连接--(CH.sub.2)组的2-碳原子一起形成一个环，以及它们的药用盐；以及将这些化合物用于医疗治疗的使用。
• Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition
  作者：Hannah J. Winfield、Michael M. Cahill、Kevin D. O'Shea、Larry T. Pierce、Thomas Robert、Sandrine Ruchaud、Stéphane Bach、Pascal Marchand、Florence O. McCarthy

  DOI：10.1016/j.bmc.2018.07.012

  日期：2018.8

  Synthesis and biological evaluation of a series of novel indole derivatives as anticancer agents is described. A bisindolylmaleimide template has been derived as a versatile pharmacophore with which to pursue chemical diversification. Starting from maleimide, the introduction of an oxygen to the headgroup (hydroxymaleimide) was initially investigated and the bioactivity assessed by screening of kinase

  描述了一系列新型的吲哚衍生物作为抗癌剂的合成和生物学评价。bisindolylmaleimide模板已作为一种通用的药效团，可以用来进行化学多样化。从马来酰亚胺开始，最初研究了向头基（羟基马来酰亚胺）中引入氧，并通过筛选激酶抑制活性，鉴定取代基衍生的选择性来评估生物活性。接下来完成羟基马来酰亚胺模板的延伸以结合吲哚氮的取代，并通过激酶抑制再次评估，从而鉴定针对GSK-3和CDK激酶的独特选择性模式。随后，使用NCI-60细胞筛选评估了比辛多利马来酰亚胺的抗癌活性，公开了针对许多细胞系，例如SNB-75 CNS癌，A498和UO-31肾，MDA MB435黑素瘤和一组白血病细胞系的生长抑制谱的发现。通过调节该模板选择性抑制激酶的潜力是显而易见的，并将为将来的选择性临床候选药物提供参考。
• Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides
  作者：Peter D. Davis、Christopher H. Hill、Geoffrey Lawton、John S. Nixon、Sandra E. Wilkinson、Steven A. Hurst、Elizabeth Keech、Susan E. Turner

  DOI：10.1021/jm00079a024

  日期：1992.1

  The design and synthesis of a series of novel inhibitors of protein kinase C (PKC) is described. These 2,3-bisarylznaleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. 2,3-Bisindolylmaleimides were the most active, and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (compound 28, IC50 0.11-mu-M). In a series of (phenylindolyl)maleimides, nitro compound 74 was most active (IC50 0.67-mu-M). Naphthalene 19 and benzothiophene 21 showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase (PKA).
• BARTH, H.;HARTENSTEIN, J.;BETCHE, H. -J.;SCHACHTELE, C.;RUDOLPH, C.;OSS. +
  作者：BARTH, H.、HARTENSTEIN, J.、BETCHE, H. -J.、SCHACHTELE, C.、RUDOLPH, C.、OSS. +

  DOI：——

  日期：——
• Maleinimid-Derivate und deren Verwendung als Arzneimittel
  申请人：GÖDECKE AKTIENGESELLSCHAFT

  公开号：EP0397060B1

  公开（公告）日：2001-11-21